<DOC>
	<DOCNO>NCT02247232</DOCNO>
	<brief_summary>This study phase III , multicenter , double-blind , placebo-controlled , parallel group comparative study evaluate efficacy safety Z-100 primary uterine cervical cancer radiotherapy . The study use central randomization dynamic allocation use bias coin minimization .</brief_summary>
	<brief_title>Randomized Study Z-100 Plus Radiation Therapy Treat Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Specific substance maruyama</mesh_term>
	<criteria>1 . FIGO stage ( 2008 ) : IIIB , cervical cancer ; 2 . Pathologically confirm squamous cell carcinoma cervix ; 3 . Patients treatmentnaive cervical cancer ; 4 . Patients without enlargement ( ≥15 mm short axis ) low abdominal paraaortic lymph node confirm CT scanning ( Patients need repeat CT scan screen CT data [ film electronic image ] within 30 day inform consent available provided central image assessment ) ; 5 . Patients ≥21 , ≤79 year age inform consent ; 6 . Patients consider possible carry intracavitary radiation radiotherapy ; 7 . Eastern Cooperative Oncology Group Performance Status : 02 ; 8 . Patients follow organ function ; ( 1 ) WBC ≥3,000/mm3 ; ( 2 ) Platelet count ≥100,000/mm3 ; ( 3 ) Hemoglobin ≥9.5 g/dL ( correction blood transfusion allow ) ; ( 4 ) Total bilirubin ≤ three ( 3 ) time upper limit reference value clinical test laboratory ; ( 5 ) AST , ALT ≤ three ( 3 ) time upper limit reference value clinical test laboratory ; ( 6 ) Renal function : 1 . If combination therapy cisplatin plan , creatinine clearance : ≥50 mL/min ; 2 . If combination therapy cisplatin plan , creatinine ≤ twice ( 2 ) upper limit reference value clinical test laboratory ; 9 . Patients willing give inform consents. ``</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>